2023

• Iland, H., Reynolds, J., McMullin, M., Martin, A., Tan, P., Taussig, D., Wong, A., Taper, J., Fraga, C., Kelly, R., et al (2023). Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation. Blood Advances, 7(11), 2580-2585. [More Information]
• Loo, S., Bilmon, I., Taper, J., Cull, G., Tiley, C., Verner, E., Hahn, U., Hiwase, D., Iland, H., Murphy, N., Murray, M., et al (2023). Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG. Blood, 142(23), 1960-1971. [More Information]

2022

• Enjeti, A., Agarwal, R., Blombery, P., Chee, L., Chua, C., Grigg, A., Hamad, N., Iland, H., Lane, S., Perkins, A., et al (2022). Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement. Pathology, 54(4), 389-398. [More Information]

2021

• Corboy, G., Othman, J., Lee, L., Wei, A., Ivey, A., Blombery, P., Agarwal, R., Fong, C., Brown, A., Scott, H., Iland, H., et al (2021). Laboratory quality assessment of candidate gene panel testing for acute myeloid leukaemia: a joint ALLG / RCPAQAP initiative. Pathology, 53(4), 487-492. [More Information]

2019

• Abadir, E., Gasiorowski, R., Lai, K., Kupresanin, F., Romano, A., Silveira, P., Lo, T., Fromm, P., Kennerson, M., Iland, H., Ho, P., Hart, D., Clark, G., et al (2019). CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation. Molecular Oncology, 13(10), 2107-2120. [More Information]
• Iland, H. (2019). Curative strategies in APL. Seminars in Hematology, 56(2), 131-138. [More Information]
• Sanz, M., Fenaux, P., Tallman, M., Estey, E., Lowenberg, B., Naoe, T., Lengfelder, E., Dohner, H., Burnett, A., Chen, S., Iland, H., et al (2019). Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood, 133(15), 1630-1643. [More Information]

2018

• Hsu, J., Bryant, C., Papadimitrious, M., Kong, B., Gasiorowski, R., Orellana, D., McGuire, H., Fazekas de St Groth, B., Joshua, D., Ho, P., Iland, H., Gibson, J., Clark, G., Fromm, P., Hart, D., et al (2018). A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission. OncoImmunology, 7(4), e1419114-1-e1419114-11. [More Information]

2017

• Mantha, S., Goldman, D., Devlin, S., Lee, J., Zannino, D., Collins, M., Douer, D., Iland, H., Litzow, M., Stein, E., et al (2017). Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood, 129(13), 1763-1767. [More Information]
• McCulloch, D., Brown, C., Iland, H. (2017). Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives. OncoTargets and Therapy, 10, 1585-1601. [More Information]
• Kommers, I., Bartley, P., Budgen, B., Latham, S., Beligaswatte, A., Supple, S., Catalano, A., Iland, H., Morley, A., Ross, D. (2017). Sensitive monitoring of acute promyelocytic leukemia by PML-RARA DNA Q-PCR. Leukemia and Lymphoma, 58(7), 1767-1769. [More Information]

2016

• Mohamed, M., Iland, H., Sharma, S., Supple, S. (2016). Atypical presentation of therapy-related acute promyelocytic leukaemia with marrow fibrosis. Pathology, 48(3), 286-288. [More Information]

2015

• He, S., Busfield, S., Ritchie, D., Hertzberg, M., Durrant, S., Lewis, I., Marlton, P., McLachlan, A., Kerridge, I., Bradstock, K., Iland, H., et al (2015). A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. Leukemia & Lymphoma, 56(5), 1406-1415. [More Information]
• Iland, H., Collins, M., Bradstock, K., Supple, S., Catalano, A., Hertzberg, M., Browett, P., Grigg, A., Firkin, F., Campbell, L., et al (2015). Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. The Lancet Haematology, 2(9), e357-e366. [More Information]

2014

• Hocking, J., Schwarer, A., Gasiorowski, R., Patil, S., Avery, S., Gibson, J., Iland, H., Ho, P., Joshua, D., Muirhead, J., et al (2014). Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocol. Leukemia & Lymphoma, 55(12), 2801-2807. [More Information]
• Iland, H., Wei, A., Seymour, J. (2014). Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care. Best Practice & Research: Clinical Haematology, 27(1), 39-52. [More Information]
• Iland, H., Seymour, J., Wei, A. (2014). Optimal approach for high-risk acute promyelocytic leukemia. Current Opinion In Hematology, 21(4), 102-113. [More Information]
• Bhattacharyya, A., Cooper, A., Hong, A., Iland, H., McNeil, C. (2014). Successful management of life-threatening disseminated intravascular coagulopathy due to metastatic melanoma. Internal Medicine Journal, 44(2), 207-208. [More Information]

2013

• Firkin, F., Iland, H. (2013). Arsenic: an old enemy now turned friend. Leukemia & Lymphoma, 54(9), 1864-1866. [More Information]
• Khoo, T., Catalano, A., Supple, S., Chong, L., Yeoh, S., Yeung, S., Iland, H. (2013). Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT. Leukemia and Lymphoma, 54(1), 186-188. [More Information]
• Gibson, J., Iland, H., Larsen, S., Brown, C., Joshua, D. (2013). Leukaemias into the 21st century - part 2: the chronic leukaemias. Internal Medicine Journal, 43(5), 484-494. [More Information]
• Bryant, C., Suen, H., Brown, R., Yang, S., Favaloro, J., Aklilu, E., Gibson, J., Ho, P., Iland, H., Fromm, P., Hart, D., Joshua, D., et al (2013). Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer Journal, 3, 1-7. [More Information]
• Iland, H., Seymour, J. (2013). Role of arsenic trioxide in acute promyelocytic leukemia. Current Treatment Options in Oncology, 14(2), 170-184. [More Information]

2012

• Iland, H., Bradstock, K., Supple, S., Catalano, A., Collins, M., Hertzberg, M., Browett, P., Grigg, A., Firkin, F., Hugman, A., et al (2012). All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood, 120(8), 1570-1580. [More Information]
• Brown, C., Larsen, S., Iland, H., Joshua, D., Gibson, J. (2012). Leukaemias into the 21st century: part 1: the acute leukaemias. Internal Medicine Journal, 42(11), 1179-1186. [More Information]
• Ling, S., Lau, K., Al-Shabeeb, A., Nikolic, A., Catalano, A., Iland, H., Horvath, N., Ho, P., Harrison, S., Fleming, S., Joshua, D., Allen, J. (2012). Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica, 97(1), 64-72. [More Information]
• Iland, H., Bradstock, K., Seymour, J., Hertzberg, M., Grigg, A., Taylor, K., Catalano, J., Cannell, P., Horvath, N., Deveridge, S., et al (2012). Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica, 97(2), 227-234. [More Information]

2009

• de Zwaan, S., Iland, H., Damian, D. (2009). Treatment of refractory pyoderma gangrenosum with intravenous immunoglobulin. Australasian Journal of Dermatology, 50(1), 56-59. [More Information]

2007

• Losco, P., Brown, R., Iland, H., Uhr, E., Lee, L., Joshua, D. (2007). An evaluation of the technical performance and clinical applications of the Beckman Coulter Access Erythropoietin immunoassay. Australian Journal of Medical Science, 28(4), 139-144.
• Young, G., Iland, H. (2007). Clinical perspectives in lymphoma. Internal Medicine Journal, 37(7), 478-484. [More Information]
• Sanders, J., Crawford, B., Gibson, J., Ho, P., Iland, H., Joshua, D. (2007). Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS). International Journal of Laboratory Hematology, 29(5), 395-397. [More Information]
• Catalano, A., Dawson, M., Somana, K., Opat, S., Schwarer, A., Campbell, L., Iland, H. (2007). The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia. Blood, 110(12), 4073-4076. [More Information]

2006

• Ling, S., Joshua, D., Gibson, J., Young, G., Iland, H., Watson, G., Ho, P. (2006). Transformation and Progression of Waldenström's Macroglobulinemia Following Cladribine Therapy in Two Cases: Natural Evolution or Iatrogenic Causation? American Journal Of Hematology, 81(2), 110-114. [More Information]

2005

• Catalano, A., Iland, H. (2005). Molecular biology of lymphoma in the microarray era. Pathology, 37(6), 508-522. [More Information]
• Iland, H., Hertzberg, M., Marlton, P. (2005). Myeloid Leukemia: Methods and Protocols. Humana Press.

2002

• Applegate, T., Iland, H., Mokany, E., Todd, A. (2002). Diagnosis and molecular monitoring of acute promyelocytic leukemia using DzyNA reverse transcription-PCR to quantify PML/RAR alpha fusion transcripts. Clinical Chemistry, 48(8), 1338-1343. [More Information]
• Stevenson, W., Vincent, P., Iland, H. (2002). Disseminated granulocytic sarcoma treated with allogeneic peripheral blood stem-cell transplantation. Leukemia and Lymphoma, 43(11), 2221-2224. [More Information]
• Applegate, T., Iland, H., Mokany, E., Todd, A. (2002). Molecular monitoring of acute promyelocytic leukemia by DzyNA reverse transcription-PCR. Clinical Chemistry, 48(10), 1858-1860.

2001

• Iland, H., Barnett, M., Pollard, J., Supple, S. (2001). A spontaneous novel XK gene mutation in a patient with McLeod syndrome. British Journal of Haematology, 115, 369-372.

2000

• Iland, H. (2000). Detection of minimal residual disease in hematologic malignancies by molecular technology. In Kerry Atkinson (Eds.), Clinical Bone Marrow and Blood Stem Cell Transplantation, (pp. 1659-1675). New York, USA: Cambridge University Press.